Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8% | news.google.com • |
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA) | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8% | news.google.com • |
(SAVA) Technical Pivots with Risk Controls | news.google.com • |
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference | globenewswire.com • |
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid? | marketbeat.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-05 | 2024-09 | -1.37 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -0.44 | -1.28 | -0.84 | -190.91% |
2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-23 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-10-02 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-10-02 | FRIEDMANN NADAV | Officer and Director | 80.05K | Conversion of Exercise of derivative security |
2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
2024-04-17 | KUPIEC JAMES WILLIAM | Officer | 4.00K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 2.75M | 67.35M | 6.54% |
2023-06-29 | Vanguard Group Inc | 2.25M | 55.16M | 5.36% |
2023-06-29 | State Street Corporation | 952.09K | 23.35M | 2.27% |
2023-06-29 | Geode Capital Management, LLC | 803.31K | 19.70M | 1.91% |
2023-06-29 | Gallacher Capital Management LLC | 583.29K | 14.30M | 1.39% |
2023-06-29 | Northern Trust Corporation | 370.64K | 9.09M | 0.88% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 30.21M | 2.94% |
2023-08-30 | iShares Russell 2000 ETF | 908.42K | 19.05M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 542.35K | 13.30M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 353.09K | 7.76M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 333.17K | 6.99M | 0.79% |
2023-05-30 | Fidelity Extended Market Index Fund | 202.34K | 4.60M | 0.48% |
Dividend | Date |
---|---|
0.75 | 2012-12-13 |
2 | 2010-12-13 |
Split | Date |
---|---|
1 : 7 | 2017-05-10 |
-
Glad my options are behind earnings (Aug 21)
-
So nothing??
-
-
Anything yet?
-
-
SAVA - Let's try this again? Presentation July 15 about SavaDx - Alzheimer's
DD
We have another Alzheimer's play here. Biogen (BIIB) submitted an Alzheimer's therapy to FDA for review on July 8 and its shares jumped 6%, but that's a higher-priced stock ($276) with a 162M float, compared to SAVA at 22M. Today INMB was up 120% on their Alzheimer's trial results.Back in May, the stock dropped from around $8 to $2.5 because of bad results from a drug study (https://www.streetinsider.com/dr/news.php?id=16890142). Now they're back with a blood-based diagnostic to detect Alzheimer’s disease (SavaDx), which they say on their website it has detected >10-fold differences between patients with Alzheimer’s and age-matched normal controls or young cognitively intact subjects. This clinical-stage program is funded by NIH as well.
Their lead neuroscientist, Lindsay H. Burns, PhD, will give a keynote presentation at the Biomarkers for Alzheimer’s Disease Summit, a virtual conference, on July 15, 2020. Dr. Burns’ talk will focus on SavaDx, the Company’s investigational diagnostic to detect Alzheimer’s disease with a simple blood test. https://finance.yahoo.com/news/cassava-sciences-keynote-presentation-savadx-200110208.html
The last time they gave a positive presentation, their stock shot up over 200% in a week https://www.nasdaq.com/articles/cassava-sciences-sava-is-up-200-in-6-days-whats-the-buzz-2019-12-30
From 3/26: Cassava Sciences is continuing the development of proprietary antibodies and other detection systems for use with SavaDx. Assuming technical success with on-going efforts, the Company expects to initiate a validation/disease specificity study with SavaDx in the second half of 2020. Cassava Sciences expects to present a technical update for SavaDx at a major scientific conference in 2020 (July 17)
-
Looks like majority of the “heavy” owners are not looking to sell until $10+ good deal team! $SAVA
-
Products and Earnings come onnnn $SAVA
Sitting on 27 AUG 21 $5 calls
-
$GOSS $INWK $SAVA $MTP
$TALO $NE $OAS $BTE $LLEXQHERE ARE SOME SECURITIES THAT ARE BEING HEAVILY LOADED, BY INSTITUTIONAL INVESTORS. AND, IF YOU BUY, YOU SHOULD SEE VERY NICE RETURNS:
$GOSS $INWK $SAVA $MTP
$TALO $NE $OAS $BTE $LLEXQNOTE ON LLEXQ:
FILED FOR BANKRUPTCY PROTECTION, BUT, IS UNDER CONTROL OF MAJOR SHAREHOLDER VARDES. VARDES IS SAID TO BE PUSHING FOR CANCELLATION OF SHARES. BUT, DOING SO WOULD CANCEL THEIR MAJORITY POSITION. SO, THAT RUMOR HAS NO MERIT. VARDES IS SAID TO BE BUYING UP ALL OF THE COMMON SHARES, ON THE OTC - THAT IS LIKELY NOT RUMOR. BUY NOW, AND, AS COMMON SHARES DRY UP, THE PRICE WILL GO MUCH HIGHER.
-
-
-
-
-
-
-
-
32 AUG 21 $5 calls on $SAVA HOLDING STRONG
-
-
Cassava Sciences (NASDAQ:SAVA) Shares Down 3.8%
news.google.com • -
Cassava Sciences stock gains on pact with ex-CEO (NASDAQ:SAVA)
news.google.com • -
Cassava Sciences (NASDAQ:SAVA) Trading Up 10.8%
news.google.com • -
(SAVA) Technical Pivots with Risk Controls
news.google.com • -
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com • -
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
marketbeat.com • -
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
seekingalpha.com • -
2 Biotech Stocks Making Moves Today
schaeffersresearch.com • -
Cassava Sciences News: Why Is SAVA Stock Trending Today?
investorplace.com • -
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
globenewswire.com • -
Get Your Money Out of These 3 Healthcare Stocks ASAP
investorplace.com • -
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
investorplace.com • -
Cassava Sciences Announces Expansion of Open-Label Extension Trials
globenewswire.com • -
Get Your Money Out of These 3 Biotech Stocks Before the End of July
investorplace.com • -
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
investorplace.com • -
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
investorplace.com • -
3 Healthcare Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Top 5 Health Care Stocks That May Explode In July
benzinga.com • -
3 Biotech Stocks to Sell in July Before They Crash & Burn
investorplace.com • -
Why Cassava Sciences Stock Is Sinking Today
fool.com •